# SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

> **NCT04684108** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 61 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma
- Hematological Malignancy

## Interventions

- **DRUG:** SG301

## Key facts

- **NCT ID:** NCT04684108
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-04
- **Primary completion:** 2024-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04684108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04684108, "SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04684108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*